First Header Logo Second Header Logo

William T. Lowther PhD

TitleProfessor
InstitutionWake Forest School of Medicine
DepartmentBiochemistry
Address
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Nelson KJ, Messier T, Milczarek S, Saaman A, Beuschel S, Gandhi U, Heintz N, Smalley TL, Lowther WT, Cunniff B. Unique Cellular and Biochemical Features of Human Mitochondrial Peroxiredoxin 3 Establish the Molecular Basis for Its Specific Reaction with Thiostrepton. Antioxidants (Basel). 2021 Jan 20; 10(2). PMID: 33498547.
      Citations:    
    2. Dushime R, Zhu Y, Wu H, Saez D, Shukla K, Brown-Harding H, Biavatti MW, Nelson KJ, Poole LB, Lowther WT, Jones PB, Furdui CM, Tsang AW. Discovery of Spilanthol Endoperoxide as a Redox Natural Compound Active against Mammalian Prx3 and Chlamydiatrachomatis Infection. Antioxidants (Basel). 2020 Dec 03; 9(12). PMID: 33287170.
      Citations:    
    3. Oliver EE, Hughes EK, Puckett MK, Chen R, Lowther WT, Howlett AC. Cannabinoid Receptor Interacting Protein 1a (CRIP1a) in Health and Disease. Biomolecules. 2020 11 27; 10(12). PMID: 33261012.
      Citations:    
    4. Milliner DS, McGregor TL, Thompson A, Dehmel B, Knight J, Rosskamp R, Blank M, Yang S, Fargue S, Rumsby G, Groothoff J, Allain M, West M, Hollander K, Lowther WT, Lieske JC. End Points for Clinical Trials in Primary Hyperoxaluria. Clin J Am Soc Nephrol. 2020 07 01; 15(7):1056-1065. PMID: 32165440.
      Citations:    
    5. Buchalski B, Wood KD, Challa A, Fargue S, Holmes RP, Lowther WT, Knight J. The effects of the inactivation of Hydroxyproline dehydrogenase on urinary oxalate and glycolate excretion in mouse models of primary hyperoxaluria. Biochim Biophys Acta Mol Basis Dis. 2020 03 01; 1866(3):165633. PMID: 31821850.
      Citations:    
    6. Booth WT, Walker NB, Lowther WT, Howlett AC. Cannabinoid Receptor Interacting Protein 1a (CRIP1a): Function and Structure. Molecules. 2019 Oct 12; 24(20). PMID: 31614728.
      Citations:    
    7. Randall LM, Dalla Rizza J, Parsonage D, Santos J, Mehl RA, Lowther WT, Poole LB, Denicola A. Unraveling the effects of peroxiredoxin 2 nitration; role of C-terminal tyrosine 193. Free Radic Biol Med. 2019 09; 141:492-501. PMID: 31323313.
      Citations:    
    8. Loberg MA, Hurtig JE, Graff AH, Allan KM, Buchan JA, Spencer MK, Kelly JE, Clodfelter JE, Morano KA, Lowther WT, West JD. Aromatic Residues at the Dimer-Dimer Interface in the Peroxiredoxin Tsa1 Facilitate Decamer Formation and Biological Function. Chem Res Toxicol. 2019 03 18; 32(3):474-483. PMID: 30701970.
      Citations:    
    9. Forshaw TE, Holmila R, Nelson KJ, Lewis JE, Kemp ML, Tsang AW, Poole LB, Lowther WT, Furdui CM. Peroxiredoxins in Cancer and Response to Radiation Therapies. Antioxidants (Basel). 2019 Jan 01; 8(1). PMID: 30609657.
      Citations:    
    10. Akter S, Fu L, Jung Y, Conte ML, Lawson JR, Lowther WT, Sun R, Liu K, Yang J, Carroll KS. Chemical proteomics reveals new targets of cysteine sulfinic acid reductase. Nat Chem Biol. 2018 11; 14(11):995-1004. PMID: 30177848.
      Citations:    
    11. Bolduc JA, Nelson KJ, Haynes AC, Lee J, Reisz JA, Graff AH, Clodfelter JE, Parsonage D, Poole LB, Furdui CM, Lowther WT. Novel hyperoxidation resistance motifs in 2-Cys peroxiredoxins. J Biol Chem. 2018 07 27; 293(30):11901-11912. PMID: 29884768.
      Citations:    
    12. Fargue S, Milliner DS, Knight J, Olson JB, Lowther WT, Holmes RP. Hydroxyproline Metabolism and Oxalate Synthesis in Primary Hyperoxaluria. J Am Soc Nephrol. 2018 06; 29(6):1615-1623. PMID: 29588429.
      Citations:    
    13. Chen X, Wu H, Park CM, Poole TH, Keceli G, Devarie-Baez NO, Tsang AW, Lowther WT, Poole LB, King SB, Xian M, Furdui CM. Discovery of Heteroaromatic Sulfones As a New Class of Biologically Compatible Thiol-Selective Reagents. ACS Chem Biol. 2017 08 18; 12(8):2201-2208. PMID: 28687042.
      Citations:    
    14. Blume LC, Patten T, Eldeeb K, Leone-Kabler S, Ilyasov AA, Keegan BM, O'Neal JE, Bass CE, Hantgan RR, Lowther WT, Selley DE, Howlett AL. Cannabinoid Receptor Interacting Protein 1a Competition with ß-Arrestin for CB1 Receptor Binding Sites. Mol Pharmacol. 2017 Feb; 91(2):75-86. PMID: 27895162.
      Citations:    
    15. Hill TK, Davis AL, Wheeler FB, Kelkar SS, Freund EC, Lowther WT, Kridel SJ, Mohs AM. Development of a Self-Assembled Nanoparticle Formulation of Orlistat, Nano-ORL, with Increased Cytotoxicity against Human Tumor Cell Lines. Mol Pharm. 2016 Mar 07; 13(3):720-8. PMID: 26824142.
      Citations:    
    16. Ritchie MK, Johnson LC, Clodfelter JE, Pemble CW, Fulp BE, Furdui CM, Kridel SJ, Lowther WT. Crystal Structure and Substrate Specificity of Human Thioesterase 2: INSIGHTS INTO THE MOLECULAR BASIS FOR THE MODULATION OF FATTY ACID SYNTHASE. J Biol Chem. 2016 Feb 12; 291(7):3520-30. PMID: 26663084.
      Citations:    
    17. Li X, Knight J, Fargue S, Buchalski B, Guan Z, Inscho EW, Liebow A, Fitzgerald K, Querbes W, Todd Lowther W, Holmes RP. Metabolism of (13)C5-hydroxyproline in mouse models of Primary Hyperoxaluria and its inhibition by RNAi therapeutics targeting liver glycolate oxidase and hydroxyproline dehydrogenase. Biochim Biophys Acta. 2016 02; 1862(2):233-9. PMID: 26655602.
      Citations:    
    18. Poynton RA, Peskin AV, Haynes AC, Lowther WT, Hampton MB, Winterbourn CC. Kinetic analysis of structural influences on the susceptibility of peroxiredoxins 2 and 3 to hyperoxidation. Biochem J. 2016 Feb 15; 473(4):411-21. PMID: 26614766.
      Citations:    
    19. Cunniff B, Newick K, Nelson KJ, Wozniak AN, Beuschel S, Leavitt B, Bhave A, Butnor K, Koenig A, Chouchani ET, James AM, Haynes AC, Lowther WT, Murphy MP, Shukla A, Heintz NH. Disabling Mitochondrial Peroxide Metabolism via Combinatorial Targeting of Peroxiredoxin 3 as an Effective Therapeutic Approach for Malignant Mesothelioma. PLoS One. 2015; 10(5):e0127310. PMID: 26011724.
      Citations:    
    20. Summitt CB, Johnson LC, Jönsson TJ, Parsonage D, Holmes RP, Lowther WT. Proline dehydrogenase 2 (PRODH2) is a hydroxyproline dehydrogenase (HYPDH) and molecular target for treating primary hyperoxaluria. Biochem J. 2015 Mar 01; 466(2):273-81. PMID: 25697095.
      Citations:    
    21. Haynes AC, Qian J, Reisz JA, Furdui CM, Lowther WT. Molecular basis for the resistance of human mitochondrial 2-Cys peroxiredoxin 3 to hyperoxidation. J Biol Chem. 2013 Oct 11; 288(41):29714-23. PMID: 24003226.
      Citations:    
    22. Chen H, Gu Z, Zhang H, Wang M, Chen W, Lowther WT, Chen YQ. Expression and purification of integral membrane fatty acid desaturases. PLoS One. 2013; 8(3):e58139. PMID: 23520490.
      Citations:    
    23. Riedel TJ, Knight J, Murray MS, Milliner DS, Holmes RP, Lowther WT. 4-Hydroxy-2-oxoglutarate aldolase inactivity in primary hyperoxaluria type 3 and glyoxylate reductase inhibition. Biochim Biophys Acta. 2012 Oct; 1822(10):1544-52. PMID: 22771891.
      Citations:    
    24. Lowther W, Lorick K, Lawrence SD, Yeow WS. Expression of biologically active human interferon alpha 2 in Aloe vera. Transgenic Res. 2012 Dec; 21(6):1349-57. PMID: 22528466.
      Citations:    
    25. Lema Tomé CM, Palma E, Ferluga S, Lowther WT, Hantgan R, Wykosky J, Debinski W. Structural and functional characterization of monomeric EphrinA1 binding site to EphA2 receptor. J Biol Chem. 2012 Apr 20; 287(17):14012-22. PMID: 22362770.
      Citations:    
    26. Jiang J, Johnson LC, Knight J, Callahan MF, Riedel TJ, Holmes RP, Lowther WT. Metabolism of [13C5]hydroxyproline in vitro and in vivo: implications for primary hyperoxaluria. Am J Physiol Gastrointest Liver Physiol. 2012 Mar 15; 302(6):G637-43. PMID: 22207577.
      Citations:    
    27. Riedel TJ, Johnson LC, Knight J, Hantgan RR, Holmes RP, Lowther WT. Structural and biochemical studies of human 4-hydroxy-2-oxoglutarate aldolase: implications for hydroxyproline metabolism in primary hyperoxaluria. PLoS One. 2011; 6(10):e26021. PMID: 21998747.
      Citations:    
    28. Lowther WT, Haynes AC. Reduction of cysteine sulfinic acid in eukaryotic, typical 2-Cys peroxiredoxins by sulfiredoxin. Antioxid Redox Signal. 2011 Jul 01; 15(1):99-109. PMID: 20712415.
      Citations:    
    29. Klomsiri C, Nelson KJ, Bechtold E, Soito L, Johnson LC, Lowther WT, Ryu SE, King SB, Furdui CM, Poole LB. Use of dimedone-based chemical probes for sulfenic acid detection evaluation of conditions affecting probe incorporation into redox-sensitive proteins. Methods Enzymol. 2010; 473:77-94. PMID: 20513472.
      Citations:    
    30. Jönsson TJ, Johnson LC, Lowther WT. Protein engineering of the quaternary sulfiredoxin.peroxiredoxin enzyme.substrate complex reveals the molecular basis for cysteine sulfinic acid phosphorylation. J Biol Chem. 2009 Nov 27; 284(48):33305-10. PMID: 19812042.
      Citations:    
    31. Cox AG, Pearson AG, Pullar JM, Jönsson TJ, Lowther WT, Winterbourn CC, Hampton MB. Mitochondrial peroxiredoxin 3 is more resilient to hyperoxidation than cytoplasmic peroxiredoxins. Biochem J. 2009 Jun 12; 421(1):51-8. PMID: 19356151.
      Citations:    
    32. Jönsson TJ, Tsang AW, Lowther WT, Furdui CM. Identification of intact protein thiosulfinate intermediate in the reduction of cysteine sulfinic acid in peroxiredoxin by human sulfiredoxin. J Biol Chem. 2008 Aug 22; 283(34):22890-4. PMID: 18593714.
      Citations:    
    33. Jönsson TJ, Murray MS, Johnson LC, Lowther WT. Reduction of cysteine sulfinic acid in peroxiredoxin by sulfiredoxin proceeds directly through a sulfinic phosphoryl ester intermediate. J Biol Chem. 2008 Aug 29; 283(35):23846-51. PMID: 18579529.
      Citations:    
    34. Murray MS, Holmes RP, Lowther WT. Active site and loop 4 movements within human glycolate oxidase: implications for substrate specificity and drug design. Biochemistry. 2008 Feb 26; 47(8):2439-49. PMID: 18215067.
      Citations:    
    35. Jönsson TJ, Johnson LC, Lowther WT. Structure of the sulphiredoxin-peroxiredoxin complex reveals an essential repair embrace. Nature. 2008 Jan 03; 451(7174):98-101. PMID: 18172504.
      Citations:    
    36. Kridel SJ, Lowther WT, Pemble CW. Fatty acid synthase inhibitors: new directions for oncology. Expert Opin Investig Drugs. 2007 Nov; 16(11):1817-29. PMID: 17970640.
      Citations:    
    37. Pemble CW, Johnson LC, Kridel SJ, Lowther WT. Crystal structure of the thioesterase domain of human fatty acid synthase inhibited by Orlistat. Nat Struct Mol Biol. 2007 Aug; 14(8):704-9. PMID: 17618296.
      Citations:    
    38. Lin Z, Johnson LC, Weissbach H, Brot N, Lively MO, Lowther WT. Free methionine-(R)-sulfoxide reductase from Escherichia coli reveals a new GAF domain function. Proc Natl Acad Sci U S A. 2007 Jun 05; 104(23):9597-602. PMID: 17535911.
      Citations:    
    39. Jönsson TJ, Lowther WT. The peroxiredoxin repair proteins. Subcell Biochem. 2007; 44:115-41. PMID: 18084892.
      Citations:    
    40. Brot N, Collet JF, Johnson LC, Jönsson TJ, Weissbach H, Lowther WT. The thioredoxin domain of Neisseria gonorrhoeae PilB can use electrons from DsbD to reduce downstream methionine sulfoxide reductases. J Biol Chem. 2006 Oct 27; 281(43):32668-75. PMID: 16926157.
      Citations:    
    41. Sun Y, Lowther W, Kato K, Bianco C, Kenney N, Strizzi L, Raafat D, Hirota M, Khan NI, Bargo S, Jones B, Salomon D, Callahan R. Notch4 intracellular domain binding to Smad3 and inhibition of the TGF-beta signaling. Oncogene. 2005 Aug 11; 24(34):5365-74. PMID: 16007227.
      Citations:    
    42. Lowther W, Wiley K, Smith GH, Callahan R. A new common integration site, Int7, for the mouse mammary tumor virus in mouse mammary tumors identifies a gene whose product has furin-like and thrombospondin-like sequences. J Virol. 2005 Aug; 79(15):10093-6. PMID: 16014973.
      Citations:    
    43. Jönsson TJ, Murray MS, Johnson LC, Poole LB, Lowther WT. Structural basis for the retroreduction of inactivated peroxiredoxins by human sulfiredoxin. Biochemistry. 2005 Jun 21; 44(24):8634-42. PMID: 15952770.
      Citations:    
    44. Montagna C, Lyu MS, Hunter K, Lukes L, Lowther W, Reppert T, Hissong B, Weaver Z, Ried T. The Septin 9 (MSF) gene is amplified and overexpressed in mouse mammary gland adenocarcinomas and human breast cancer cell lines. Cancer Res. 2003 May 01; 63(9):2179-87. PMID: 12727837.
      Citations:    
    Lowther's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (231)
    Explore
    _
    Co-Authors (11)
    Explore
    _
    Similar People (49)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _